Inflammatory Activity on Natalizumab Predicts Short-Term but Not Long-Term Disability in Multiple Sclerosis.

This shift over time was driven by highly significant year-on-year increases in disability progression specifically in those without on-treatment inflammatory activity.

also in 132,142 other papers

Paradoxically, there was a trend towards inflammatory activity on treatment (first year Modified Rio Score, relapses, and MRI activity) predicting a lower risk of EDSS progression by years 3–7, although this did not reach statistical significance.

also in 111,027 other papers